Pimavanserin in Patients w Alzheimer's Disease Psychosis (ACP-103-019)

• Research type

  Research Study

• Full title

  A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer’s Disease

• IRAS ID

  135084

• Contact name

  Clive G Ballard

• Contact email

  Clive.ballard@kcl.ac.uk

• Sponsor organisation

  ACADIA Pharmaceuticals Inc.

• Eudract number

  2010-020008-31

• ISRCTN Number

  0

• Clinicaltrials.gov Identifier

  0

• REC name

  Wales REC 3

• REC reference

  13/WA/0271

• Date of REC Opinion

  25 Oct 2013

• REC opinion

  Further Information Favourable Opinion